Third Consensus of Granada on Drug Related Problems (DRP) and Negative Outcomes associated with Medication (NOM)
Keywords:
Drug Related Problems, Negative Outcomes associated with Medication, Pharmaceutical care, Drug use, Clinical outcomesAbstract
As a consequence of the widespread prevalence of problems associated with the use of medicines, the concept of DrugRelated Problems (DRP) was established in 1990 in Spain. Through the fi rst Consensus of Granada in 1998, a defi nitionof this term was reached, in which the varying related problems were classifi ed into 6 categories. With the experiencegained from this defi nition and classifi cation, a second consensus was subsequently published in 2002, which in turn hasnow lead to the third Consensus of Granada on Drug Related Problems (DRP) and Negative Outcomes associated withMedication (NOM), recognising the signifi cance of DRPs as elements of process and as the cause of (NOM). In thisthird work, DRPs and NOMs are defi ned, and a list of DRPs and a classifi cation of NOMs has been compiled. Finally,the defi nition of Pharmacotherapy Monitoring from the Consensus on Pharmaceutical Care of the Ministry of Healthand Consumption of Spain published in 2001 was adapted, in accordance with new concepts of MRP and NOM.Downloads
References
Faus MJ. Atención Farmaceútica como respuesta a una necesidad social. Ars Pharm 2000; 41:137-143.
Fernández-Llimós F, Tuneu L, Baena MI, García-Delgado A, Faus MJ. Morbidity and mortality associated with pharmacotherapy.
Evolution and current concept of drug-related problems. Curr Pharm Desing. 2004; 10: 3947-67.
Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990; 24: 1093-7.
Fernández-Llimós, Faus MJ, Gastelurrutia MA, Baena MI, Martínez Martinez F. Evolución del concepto de problemas relacionados con los medicamentos: resultados como el centro de un nuevo paradigma. Seguim Farmacoter 2005; 3: 167-188.
Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice. New York; McGraw-Hil; 1998.
Alvarez de Toledo F, Dago AM, Eyaralar T. Problemas relacionados con medicamentos. En: Master de Atención Farmacéutica
Comunitaria. Volumen VII. Valencia. Universidad de Valencia; 1999. p. 15-38
Panel de consenso ad hoc. Consenso de Granada sobre Problemas relacionados con Medicamentos. Pharmaceutical Care 1999; 1: 107-112.
Sánchez Navarro A. Régimen posológico inadecuado: Problema relacionado con medicamentos (PRM) no clasificado. Pharm Care Esp 1999;1:382.
Martinez-Romero F, Fernández-Llimós F, Faus MJ. Régimen posológico inadecuado: Problema relacionado con medicamentos
(PRM) si clasificado. Pharm Care Esp 1999; 1: 458.
Diez MV. Clasificación de problemas relacionados con la medicación según el consenso de Granada. Sugerencia de definición para el PRM 3. Pharm Care Esp 2000;2: 139-140.
Panel de Consenso. Segundo Consenso de Granada sobre Problemas Relacionados con Medicamentos. Ars Pharm 2002; 43: 175-184.
WONCA Classification Committee. An international glossary for general/family practice. Fam Pract 1995; 12: 341-369.
Donabedian A. The quality of medical care. Science 1978; 200: 856-864.
Badía X, Bigorra J. La Investigación de Resultados en Salud: de la evidencia a la práctica clínica. Xavier Badía Llanch (Ed.). Barcelona: Edimac, 2000.
Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44: 166-206.
Gouvela WA, Bungay KM, Massaro FJ, Ware JE, Jr.: Paradigm for the management of outcomes. Am J Hosp Pharm 1999;48:1912-6
Kozma CM, Reeder CE, Schulz RM. Economic, clinical and humanistic outcomes: a planning model for pharmacoeconomic
research. Clin Ther 1993; 15(6): 1121-1132.
Schaefer M: Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc. Pharm World Sci 2002;24(4):120-7.
American Society of Health-System Pharmacist. ASPH guidelines on a standardized method for pharmaceutical care. Am J Health-Syst Pharm 1996; 53: 1713-16
Van Mil JWF, Westerlund LOT, Hersberger KE, Schaefer MA. Drug-related problem classification systems. Ann Pharmacother 2004; 38: 859-67
Abu Ruz SM, Bulatova NR,Yousef AM. Validation of comprehensive classification tool for treatment-related problems. Pharm World Sci 2006; 28: 222-232.
Fernández-Llimós F, Faus MJ. From “drug-related problems” to “negative clinical outcomes”. Am J Health-Syst Pharm 2005; 62: 2348-50.
Amariles P, Fernández-Llimós F, Faus MJ. Terminology for problems related to drug use. Am J Health-Syst Pharm 2006; 63: 616-617.
Aronson JK, Ferner RE Clarification of terminology in drug safety. Drug safety 2005; 28:851-870
Otero-López MJ, Alonso-Hernández P, Maderuelo-fernández JA, Garrido-Corro B, Domínguez-Gil A, Sánchez-Rodríguez A Acontecimientos adversos prevenibles causados por medicametnos en pacientes hospitalizados. Med Clin (Barc) 2006; 126: 81-87
Ferner RE, Aronson JK. Clarification of terminology in medications errors. Definitions and classification. Drug safety 2006; 29: 1011-1022
Baena MI, Faus MJ, Fajardo PC, Luque FM, Sierra F, Martínez-Olmos J, et. al. Medicine-related problems resulting in emergency department visits. Eur J Pharmacol 2006; 62: 387-393.
Grupo de Consenso. Documento de Consenso en Atención Farmacéutica. Ministerio de Sanidad y Consumo. Ars Pharm 2001; 42 : 223-243.
FORO. Declaración Institucional. Farmacéuticos 2006
FORO. Documento sobre PRM y RNM: conceptos y definiciones. Farmacéuticos 2006; 315:28-29
Grupo de Investigación en Atención Farmacéutica de la Universidad de Granada. Guía del Método Dáder para el Seguimiento Farmacoterapéutico. 3ª Edición. Disponible en: www.ugr.es/~cts131/
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
